Secukinumab, a human IgG1 monoclonal antibody which was approved in 2015 for the treatment of plaque psoriasis by targeting IL-17A, and has demonstrated greater efficacy than ustekinumab [19, 36]. This evidence concerns the gene IL17A and psoriasis vulgaris.